Cargando…
Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial
BACKGROUND: Despite complete resection, disease-free survival (DFS) of patients with cholangiocarcinoma (CCA) is less than 65 % after one year and not more than 35 % after three years. For muscle invasive gallbladder carcinoma (GBCA), prognosis is even worse, with an overall survival (OS) of only 30...
Autores principales: | Stein, Alexander, Arnold, Dirk, Bridgewater, John, Goldstein, David, Jensen, Lars Henrik, Klümpen, Heinz-Josef, Lohse, Ansgar W., Nashan, Björn, Primrose, John, Schrum, Silke, Shannon, Jenny, Vettorazzi, Eik, Wege, Henning |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520064/ https://www.ncbi.nlm.nih.gov/pubmed/26228433 http://dx.doi.org/10.1186/s12885-015-1498-0 |
Ejemplares similares
-
Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection
por: von Felden, Johann, et al.
Publicado: (2017) -
Adjuvant Gemcitabine-Oxaliplatin (GEMOX) after Curative Surgery in High-risk Patients with Cholangiocarcinoma
por: Paule, Bernard, et al.
Publicado: (2010) -
Persistence of gastrointestinal symptoms in irritable bowel syndrome and ulcerative colitis: study protocol for a three-arm randomised controlled trial (SOMA.GUT-RCT)
por: Löwe, Bernd, et al.
Publicado: (2022) -
A Multicenter Phase II Trial of Gemcitabine Plus Oxaliplatin in Unresectable Gallbladder Cancer
por: Woo, Sang Myung, et al.
Publicado: (2013) -
High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection
por: von Felden, Johann, et al.
Publicado: (2017)